Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
Erythropoietin in HIE Neonate
- Conditions
- Interventions
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-10
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 3
- Registration Number
- NCT06590155
- Locations
- 🇪🇬
Assiut university children hospital, Assiut, Egypt
PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 120
- Registration Number
- NCT06542393
- Locations
- 🇧🇷
Leonardo Ohashi, São Paulo, SAO Paulo, Brazil
EPO for Postop Delirium in Elderly Patients
- Conditions
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 76
- Registration Number
- NCT06178835
- Locations
- 🇰🇷
Department of Anesthesiology and Pain medicine, Severance Hospital, Seoul, South Korea, Seoul, Korea, Republic of
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 18
- Registration Number
- NCT06135259
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 200
- Registration Number
- NCT05931718
- Locations
- 🇮🇹
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Colorado-Oregon Altitude Study
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- University of Oregon
- Target Recruit Count
- 121
- Registration Number
- NCT05734716
- Locations
- 🇺🇸
Colorado Mountain College, Leadville, Colorado, United States
🇺🇸Cardiopulmonary and Respiratory Physiology Lab, Eugene, Oregon, United States
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 504
- Registration Number
- NCT05395195
- Locations
- 🇧🇩
Dhaka Medical College, Dhaka, Bangladesh
🇮🇳Bangalore Medical College, Bangalore, India
🇮🇳Lokmanya Tilak Municipal Medical College, Mumbai, India
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT05325073
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Pharmacological Countermeasures for High Altitude
- Conditions
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 18
- Registration Number
- NCT05300477
- Locations
- 🇺🇸
USARIEM, Natick, Massachusetts, United States
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 150
- Registration Number
- NCT05181735
- Locations
- 🇫🇷
CHU Nantes - Hôtel Dieu, Nantes, France
🇫🇷Clinique de l'Europe, Amiens, France
🇫🇷CHR d'Orléans, Orléans, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.